Price of Eliquis reduced by 3.5%... Kanarb by 1.7% each

Due to increased sales

Price of 6 products whose PVA negotitions are complete will be reduced by 1st of next month

Price of PVA A Type Mavenclad will fall by 6.9%

Merck's Mavenclad tab.

 

(cladribine), which is used to treat relapsing-remitting multiple sclerosis, has become subject to price cuts under the price-volume agreement and will be sold at a 6.9% lower price starting next month.

 

The price of Boryung’s flagship hypertension drug, Kanarb (fimasartan potassium trihydrate), will be reduced by 1.7% for each dose, and the price of BMS Korea Eliquis will also be reduced by 3.5% for each dose.

 

According to industry sources on the 21st, the Ministry of Health and Welfare is planning to revise the 'Drug Reimbursement List and Reimbursement Ceiling Amount Table' and apply it on the 1st of next month.

 

A total of 6 products will be applied PVA price cuts.

 

One is subject to ‘PVA Type A’ and the other 5 are subject to ‘PVA Type B’ and the subject drugs have been conducting negotiations with the National Health Insurance Service until now.

 

◆PVA Type A = Price of only 1 drug classified as 'type A' will be reduced after completing negotiations with the government.

 

Among new drugs listed as negotiable after the introduction of the drug price negotiation system, the government applies PVA A type to drugs whose claims amount in the same product category exceeds the expected claims amount by over 30%.

 

By same product category, drugs that have the same company name, route of administration, ingredient, and formulation are classified as drugs of the same product category.

 

The drug subject to ‘Type A’ price reduction is Merck’s Mavenclad Tab.

 

Its price is set to be reduced by 6.9%, and the price cut will be applied starting on the 1st of next month.

 

◆PVA Type B = Also, 5 drugs that were classified as Type B will receive price discounts this time.

 

The government applies PVA Type B and reduces the price of drugs ▲whose price ceiling had been already adjusted according to Type A, ▲ whose claims amount increased by over 60% from the previous year without undergoing Type A negotiations, or 4 years after receiving Type A negotiations, or ▲ has increased by over 10% but the increased amount exceeds KRW 5 billion and does not fall under PVA Type A.

 

By each item, the price of 60mg and 120mg doses of Boryung’s Kanab Tab.

 

will be reduced by 1.7%, respectively.

 

The price of its 30mg dose product will be reduced by 1.8%.

 

Eliquis's insurance drug prices will fall by 3.5% each for both the 2.5mg and 5mg doses.